BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:29 PM
 | 
Aug 27, 2012
 |  BC Extra  |  Clinical News

Merck updates CV pipeline

Merck & Co. Inc. (NYSE:MRK) provided an update on its cardiovascular programs Monday, including a reanalysis of data from the Phase III DEFINE trial of anacetrapib using a more accurate method for measuring LDL-C. The pharma now expects the cholesteryl ester transfer protein (CETP) inhibitor to produce a reduction from baseline in LDL-C of about 25-35% using the new...

Read the full 281 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >